Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > BUSINESS
BUSINESS
- Genzyme Changes Distributor of 3 Products Including Thymoglobulin to sanofi-aventis
April 4, 2012
- Abbott Receives Approval for Diagnostic Agent for Identification of Patients for Xalkori Administration
April 4, 2012
- Mochida Aims for Sales of Over 100 Billion Yen in FY2014: New Midterm Management Plan
April 4, 2012
- Top Leaders Stress Importance of Globalization in Addresses to Incoming New Graduates
April 4, 2012
- ALK Inhibitor Xalkori Approved, to Be Provided before NHI Listing: Pfizer Japan
April 3, 2012
- Eisai Licenses Bexarotene Rights to Minophagen in Emerging Countries
April 3, 2012
- Kowa Sets Up Kowa Generic for Generic Business
April 3, 2012
- Kyowa Kirin Applies for Novel Parkinson’s Disease Treatment KW-6002
April 3, 2012
- Shionogi Acquires Global Rights for OncoTheraphy’s Cancer Vaccines
April 2, 2012
- Kyowa Kirin’s Expected Mainstay POTELIGEO Approved
April 2, 2012
- GSK, DSP Begin Copromotion of Paxil CR Tablets from April
April 2, 2012
- Toray, Taiho Terminate Co-Development of β3-Adrenoceptor Agonist
April 2, 2012
- NanoCarrier Enters into Joint Research Agreement with Eisai for Its Drug Discovery Platform Technology
April 2, 2012
- Astellas Enters into Partnership with US Company to Develop, Market Fidaxomicin in Japan
April 2, 2012
- Novartis Files for Add’l Indication of DME for Lucentis
April 2, 2012
- Tempstaff, IUK to Form PV Management Joint Venture in May
March 30, 2012
- Astellas, Pfizer Extend Lipitor Licensing Term
March 30, 2012
- Daiichi Sankyo Enters Research Collaboration Agreement on Diabetes Therapy with US Venture Company
March 30, 2012
- Otsuka Chemical to Split Up Glycotechnology Laboratory to Make It New Company
March 30, 2012
- More Than 70% of Doctors Say “Frequency of Meetings Will Not Change” Despite Review of Entertainment: CareNet Survey
March 29, 2012
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…